Active — Not RecruitingNot Applicable

Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description

Vietnam100 participantsStarted 2021-10-04

Plain-language summary

This study aims to evaluate the use of Next Generation Sequencing (NGS) to detect circulating tumor DNA in gastric cancer patients after gastrectomy

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Male or Female patients aged 18 years and older
✓. Histologically proven primary gastric adenocarcinoma before surgery
✓. Clinical stage is locally advanced cT2-4a any N and M0
✓. In initial evaluation, patient can undergo radical gastrectomy and lymphadenectomy
✓. No preoperative therapy, including chemotherapy and radiotherapy
✓. No known cancer diagnosis within last five years
✓. Signed informed consent

The sensitivity of MRD detection using ctDNA as the biomarker

Timeframe: 2 years after surgery

The specificity of MRD detection using ctDNA as the biomarker

Timeframe: 2 years after surgery

NCT IDNCT05029869

SponsorUniversity Medical Center Ho Chi Minh City (UMC)

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-30